Noveris Health Sciences Inc.
Noveris Health Sciences Inc. Provides Clarifying News Release Regarding Life Offering And Other Disclosure
Healthcare
Page 31- Apr 20, 2026 · 09:15 · OTC · Routine +01
Clinical Validation Confirmed, But Capital Constraints Remain Key Risk
Ocumetics Reports Improvement in Six Month First-in-Human Results Meaningful Improvements in Patient Quality of Life
- Apr 20, 2026 · 08:50 · VPT · Routine +02
Ventripoint Wins Gold Edison Award But Cash Burn and Dilution Risks Persist
Ventripoint's VMS+(TM) 4.0 Recognized with Gold Edison Award, Validating Leadership and Future Potential
- Apr 20, 2026 · 08:30 · KETA · Routine −03
Legal Scrutiny Amidst Capital Erosion
TripSitter Announces Discovery Notice
- Apr 20, 2026 · 08:15 · HELP · Routine −04
Management Instability Clouds Near-Term Catalysts Despite Strong Cash Position
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions
- Apr 20, 2026 · 08:01 · PHRM · Routine +05
PharmaTher Seeks Regulatory Tailwinds Amidst Price Slump
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
- Apr 20, 2026 · 08:00 · CSCI · Routine +06
COSCIENS Biopharma Proposes Share Consolidation to Cut Reporting Costs and Exit U.S. Registry
COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations
- Apr 20, 2026 · 08:00 · HELP · Material −07
Tagline: Leadership Turmoil Overshadows Clinical Wins as Helus Pharma CEO Departs Ahead of Pivotal Phase 3 Readout
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer
- Apr 20, 2026 · 07:30 · BCT · Routine +08
BriaCell Stabilizes Near Multi-Year Lows as Phase 3 QOL Data Validates Safety Profile Ahead of Top-Line Efficacy Readout
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
- Apr 20, 2026 · 07:01 · EYE · Routine +09
Micro-cap optical tech firm secures US commercialization partner
Rise Nano Optics Announces Strategic Partnership with Sierra Optical Lab to Produce and Commercialize SpectraGuard(TM) Lenses in the United States
- Apr 20, 2026 · 07:00 · AIAI · Routine +10
NetraMark Commentary on Psychedelic Executive Order Fails to Halt Downtrend Despite Insider Buying
Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory-Grade Trial Design in Psychedelic Development
- Apr 20, 2026 · 07:00 · CNVI · Routine +11
FDA Clearance Confirms Timeline, But Cash Burn Threatens Commercial Launch Viability
Conavi Medical Announces FDA 510(k) Clearance of its Next-Generation Hybrid IVUS-OCT System for Intravascular Imaging
- Apr 20, 2026 · 06:00 · LOBE · Routine +12
Lobe Sciences Secures Funding for Sickle Cell Candidate Amid Balance Sheet Strengthening
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update
- Apr 20, 2026 · 02:30 · 4565 · Routine +13
Nxera Pharma Milestone Payments Offset Cash Burn as Pipeline Validation Accelerates in APAC and US
Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases
- Apr 17, 2026 · 19:00 · ONCO14
Onco-Innovations Management Overhaul Amidst Severe Valuation Erosion and Dilution Concerns
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development